GTHX G1 Pharma: Nilai Akuntansi saben Saham

The book value per share determines the liquidation basis for G1 Therapeutics, Inc. (GTHX), whose CDK4/6 inhibition patents create defensive barriers. Revenues are based on the sale of Cosela and partnership royalties. Expansion into Europe and Asia is broadening the network of oncology center clients. The current 0.47 indicator reflects the status of equity, smoothing out market noise for potential buyers.

This metric reflects the sensitivity of equity to operating losses, measuring the residual value of assets minus liabilities per share. For G1 Therapeutics, Inc. (GTHX), which is depleting reserves on costly R&D without sustainable revenue, the net asset value per share serves as an indicator of the burn rate of its financial foundation and the efficiency of securing external financing.